Hayward, CA – September 9, 2025 – Pulse Biosciences, a pioneer in bioelectric medicine and nanosecond pulsed field ablation (nsPFA™) technology, announced today that the U.S. Food and Drug Administration (FDA) has granted an Investigational Device Exemption (IDE) for its nsPFA Cardiac Surgery System. This milestone enables the company to initiate a pivotal clinical study evaluating the use of nsPFA during cardiac surgeries to treat atrial fibrillation (AF).
Background & Significance
Breakthrough Device Designation
In July 2024, the FDA previously awarded Pulse Biosciences Breakthrough Device designation for its Cardiac Surgery System, designed to produce rapid, transmural, nonthermal cardiac ablation via a surgical clamp, potentially revolutionizing AF treatment.
Steady Progress Toward Clinical Evaluation
Earlier in 2025, Pulse had signaled its intention to submit an IDE, with plans to commence a pivotal clinical trial by mid-2025 investors.pulsebiosciences.comMassDevice. The IDE approval confirms those plans are advancing on schedule.
Science Significance
Nanosecond pulsed field ablation represents a paradigm shift in electrophysiology. Unlike thermal ablation methods such as radiofrequency or cryotherapy, nsPFA uses ultrafast, high-intensity electric pulses to create precise lesions in cardiac tissue without damaging surrounding structures. Preclinical studies have shown nsPFA can achieve rapid, reproducible transmural lesions in fractions of a second, potentially offering surgeons unprecedented control and efficiency during AF treatment.
Regulatory Significance
Advertisement
The IDE approval builds on FDA’s earlier Breakthrough Device designation for Pulse’s nsPFA Cardiac Surgery System. This dual recognition signals strong regulatory confidence in the technology’s novelty and potential to address an unmet clinical need. With IDE approval in hand, Pulse Biosciences is now authorized to begin human trials—an essential milestone toward a future Premarket Approval (PMA) submission. This step underscores FDA’s willingness to accelerate pathways for innovative therapies in electrophysiology.
Business Significance
For Pulse Biosciences, the IDE represents both validation and acceleration. The company now enters a critical phase of clinical development that could expand its commercial footprint beyond dermatology and solidify its presence in cardiology. With AF representing one of the most prevalent and costly cardiac conditions worldwide, the addressable market is vast. IDE approval also enhances investor confidence, offering a tangible regulatory milestone that supports strategic partnerships, capital inflow, and potential licensing opportunities.
Patients’ Significance
Atrial fibrillation affects millions globally, increasing risks of stroke, heart failure, and reduced quality of life. Current surgical ablation techniques, though effective, are time-consuming and carry risks of collateral tissue damage. nsPFA’s precision and speed could significantly reduce procedure times, limit complications, and improve long-term outcomes for patients. For those undergoing cardiac surgery, this innovation offers the promise of safer, faster, and more durable treatment for AF.
Policy Significance
The IDE approval illustrates how U.S. regulatory frameworks are adapting to support next-generation medical technologies. It reflects FDA’s ongoing commitment to balancing patient safety with innovation in device development. Policymakers and healthcare systems may see this as a case study in accelerating transformative technologies while maintaining rigorous oversight, potentially shaping future guidelines for bioelectric and energy-based therapies.
With IDE approval secured, Pulse Biosciences now transitions from promise to proof. The forthcoming clinical trial will not only test the safety and efficacy of nsPFA in surgical AF ablation but may also define a new frontier in cardiac electrophysiology. For regulators, industry, clinicians, and patients alike, this milestone represents more than a regulatory green light—it signals the beginning of a scientific and clinical journey that could reshape the treatment landscape for one of the most pressing cardiovascular disorders of our time.
Source: Pulse Biosciences Press Release
